Annual Revenue
$176.23 M
+$64.93 M+58.34%
31 December 2023
Summary:
Sangamo Therapeutics annual revenue is currently $176.23 million, with the most recent change of +$64.93 million (+58.34%) on 31 December 2023. During the last 3 years, it has risen by +$58.04 million (+49.11%). SGMO annual revenue is now at all-time high.SGMO Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Revenue
$49.41 M
+$49.06 M+13779.78%
30 September 2024
Summary:
Sangamo Therapeutics quarterly revenue is currently $49.41 million, with the most recent change of +$49.06 million (+13779.78%) on 30 September 2024. Over the past year, it has increased by +$40.01 million (+425.77%). SGMO quarterly revenue is now -68.72% below its all-time high of $157.96 million, reached on 31 March 2023.SGMO Quarterly Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM Revenue
$52.29 M
+$40.01 M+325.93%
30 September 2024
Summary:
Sangamo Therapeutics TTM revenue is currently $52.29 million, with the most recent change of +$40.01 million (+325.93%) on 30 September 2024. Over the past year, it has dropped by -$149.13 million (-74.04%). SGMO TTM revenue is now -78.30% below its all-time high of $241.03 million, reached on 31 March 2023.SGMO TTM Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SGMO Revenue Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +58.3% | +425.8% | -74.0% |
| 3 y3 years | +49.1% | +73.0% | -51.8% |
| 5 y5 years | +108.7% | +125.0% | -29.7% |
SGMO Revenue High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +59.2% | -68.7% | >+9999.0% | -78.3% | +325.9% |
| 5 y | 5 years | at high | +108.7% | -68.7% | >+9999.0% | -78.3% | +325.9% |
| alltime | all time | at high | >+9999.0% | -68.7% | >+9999.0% | -78.3% | +6780.4% |
Sangamo Therapeutics Revenue History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $49.41 M(>+9900.0%) | $52.29 M(+325.9%) |
| June 2024 | - | $356.00 K(-26.0%) | $12.28 M(-34.5%) |
| Mar 2024 | - | $481.00 K(-76.4%) | $18.76 M(-89.4%) |
| Dec 2023 | $176.23 M(+58.3%) | $2.04 M(-78.3%) | $176.23 M(-12.5%) |
| Sept 2023 | - | $9.40 M(+37.5%) | $201.42 M(-7.8%) |
| June 2023 | - | $6.83 M(-95.7%) | $218.48 M(-9.4%) |
| Mar 2023 | - | $157.96 M(+480.1%) | $241.03 M(+116.6%) |
| Dec 2022 | $111.30 M(+0.5%) | $27.23 M(+2.9%) | $111.30 M(-0.7%) |
| Sept 2022 | - | $26.46 M(-9.9%) | $112.06 M(-1.8%) |
| June 2022 | - | $29.38 M(+4.1%) | $114.16 M(+1.3%) |
| Mar 2022 | - | $28.23 M(+0.9%) | $112.65 M(+1.8%) |
| Dec 2021 | $110.70 M(-6.3%) | $27.99 M(-2.0%) | $110.70 M(+2.0%) |
| Sept 2021 | - | $28.56 M(+2.5%) | $108.52 M(-21.2%) |
| June 2021 | - | $27.87 M(+6.1%) | $137.72 M(+4.8%) |
| Mar 2021 | - | $26.28 M(+1.9%) | $131.40 M(+11.2%) |
| Dec 2020 | $118.19 M(+15.4%) | $25.80 M(-55.3%) | $118.19 M(-19.7%) |
| Sept 2020 | - | $57.76 M(+168.0%) | $147.24 M(+32.1%) |
| June 2020 | - | $21.55 M(+64.8%) | $111.44 M(+3.7%) |
| Mar 2020 | - | $13.08 M(-76.2%) | $107.43 M(+4.9%) |
| Dec 2019 | $102.43 M(+21.3%) | $54.85 M(+149.8%) | $102.43 M(+37.6%) |
| Sept 2019 | - | $21.96 M(+25.1%) | $74.41 M(-2.1%) |
| June 2019 | - | $17.55 M(+117.4%) | $76.02 M(-4.8%) |
| Mar 2019 | - | $8.07 M(-69.9%) | $79.89 M(-5.4%) |
| Dec 2018 | $84.45 M(+131.0%) | $26.84 M(+13.9%) | $84.45 M(+19.5%) |
| Sept 2018 | - | $23.56 M(+10.0%) | $70.69 M(+19.9%) |
| June 2018 | - | $21.42 M(+69.5%) | $58.94 M(+28.8%) |
| Mar 2018 | - | $12.64 M(-3.4%) | $45.78 M(+25.2%) |
| Dec 2017 | $36.57 M(+88.6%) | $13.08 M(+10.7%) | $36.57 M(+12.8%) |
| Sept 2017 | - | $11.81 M(+43.1%) | $32.41 M(+38.4%) |
| June 2017 | - | $8.25 M(+141.0%) | $23.42 M(+24.1%) |
| Mar 2017 | - | $3.42 M(-61.6%) | $18.87 M(-2.7%) |
| Dec 2016 | $19.39 M(-51.0%) | $8.92 M(+216.0%) | $19.39 M(-1.0%) |
| Sept 2016 | - | $2.82 M(-23.7%) | $19.59 M(-22.7%) |
| June 2016 | - | $3.70 M(-6.1%) | $25.33 M(-15.5%) |
| Mar 2016 | - | $3.94 M(-56.8%) | $29.99 M(-24.2%) |
| Dec 2015 | $39.54 M(-13.8%) | $9.12 M(+6.4%) | $39.54 M(-12.9%) |
| Sept 2015 | - | $8.57 M(+2.5%) | $45.37 M(-7.8%) |
| June 2015 | - | $8.36 M(-38.0%) | $49.22 M(-4.0%) |
| Mar 2015 | - | $13.49 M(-9.8%) | $51.24 M(+11.7%) |
| Dec 2014 | $45.87 M(+90.1%) | $14.95 M(+20.4%) | $45.87 M(+21.4%) |
| Sept 2014 | - | $12.42 M(+19.6%) | $37.79 M(+21.6%) |
| June 2014 | - | $10.38 M(+28.0%) | $31.08 M(+12.5%) |
| Mar 2014 | - | $8.12 M(+18.2%) | $27.63 M(+14.5%) |
| Dec 2013 | $24.13 M(+11.4%) | $6.87 M(+20.4%) | $24.13 M(-7.9%) |
| Sept 2013 | - | $5.71 M(-17.7%) | $26.20 M(+3.2%) |
| June 2013 | - | $6.93 M(+50.0%) | $25.40 M(+10.2%) |
| Mar 2013 | - | $4.62 M(-48.2%) | $23.04 M(+6.4%) |
| Dec 2012 | $21.66 M(+109.9%) | $8.93 M(+82.0%) | $21.66 M(+23.9%) |
| Sept 2012 | - | $4.91 M(+7.3%) | $17.47 M(+21.1%) |
| June 2012 | - | $4.57 M(+41.1%) | $14.42 M(+26.9%) |
| Mar 2012 | - | $3.24 M(-31.7%) | $11.36 M(+10.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2011 | $10.32 M(-50.4%) | $4.75 M(+155.7%) | $10.32 M(+0.6%) |
| Sept 2011 | - | $1.86 M(+22.7%) | $10.26 M(-9.6%) |
| June 2011 | - | $1.51 M(-31.2%) | $11.35 M(-30.6%) |
| Mar 2011 | - | $2.20 M(-53.1%) | $16.36 M(-21.4%) |
| Dec 2010 | $20.80 M(-6.2%) | $4.69 M(+59.3%) | $20.80 M(-21.1%) |
| Sept 2010 | - | $2.94 M(-54.9%) | $26.36 M(-4.1%) |
| June 2010 | - | $6.53 M(-1.9%) | $27.48 M(+7.0%) |
| Mar 2010 | - | $6.65 M(-35.1%) | $25.68 M(+15.7%) |
| Dec 2009 | $22.19 M(+37.1%) | $10.24 M(+152.1%) | $22.19 M(+18.1%) |
| Sept 2009 | - | $4.06 M(-14.0%) | $18.78 M(+1.7%) |
| June 2009 | - | $4.73 M(+49.7%) | $18.46 M(+11.4%) |
| Mar 2009 | - | $3.16 M(-53.8%) | $16.58 M(+2.4%) |
| Dec 2008 | $16.19 M(+77.9%) | $6.83 M(+82.5%) | $16.19 M(+33.6%) |
| Sept 2008 | - | $3.75 M(+31.8%) | $12.12 M(+13.3%) |
| June 2008 | - | $2.84 M(+2.8%) | $10.70 M(+2.5%) |
| Mar 2008 | - | $2.77 M(-0.1%) | $10.44 M(+14.8%) |
| Dec 2007 | $9.10 M(+15.4%) | $2.77 M(+19.0%) | $9.10 M(+6.7%) |
| Sept 2007 | - | $2.33 M(-10.0%) | $8.52 M(+6.8%) |
| June 2007 | - | $2.58 M(+81.7%) | $7.98 M(+11.3%) |
| Mar 2007 | - | $1.42 M(-35.2%) | $7.17 M(-9.1%) |
| Dec 2006 | $7.88 M(+217.4%) | $2.19 M(+23.3%) | $7.88 M(+11.2%) |
| Sept 2006 | - | $1.78 M(+0.1%) | $7.09 M(+23.9%) |
| June 2006 | - | $1.78 M(-16.8%) | $5.72 M(+31.1%) |
| Mar 2006 | - | $2.14 M(+52.9%) | $4.36 M(+75.7%) |
| Dec 2005 | $2.48 M(+88.9%) | $1.40 M(+239.1%) | $2.48 M(+93.1%) |
| Sept 2005 | - | $412.00 K(-1.4%) | $1.29 M(+22.9%) |
| June 2005 | - | $418.00 K(+63.3%) | $1.05 M(+37.6%) |
| Mar 2005 | - | $256.00 K(+28.0%) | $760.00 K(-42.2%) |
| Dec 2004 | $1.31 M(-49.0%) | $200.00 K(+16.3%) | $1.31 M(-37.9%) |
| Sept 2004 | - | $172.00 K(+30.3%) | $2.12 M(-13.7%) |
| June 2004 | - | $132.00 K(-83.7%) | $2.45 M(-13.6%) |
| Mar 2004 | - | $811.00 K(-19.1%) | $2.84 M(+10.1%) |
| Dec 2003 | $2.58 M(-40.6%) | $1.00 M(+97.8%) | $2.58 M(-36.2%) |
| Sept 2003 | - | $507.00 K(-2.1%) | $4.04 M(-11.1%) |
| June 2003 | - | $518.00 K(-6.0%) | $4.54 M(+3.5%) |
| Mar 2003 | - | $551.00 K(-77.6%) | $4.39 M(+1.2%) |
| Dec 2002 | $4.34 M(-11.1%) | $2.46 M(+143.5%) | $4.34 M(+7.4%) |
| Sept 2002 | - | $1.01 M(+176.5%) | $4.04 M(+7.2%) |
| June 2002 | - | $366.00 K(-26.9%) | $3.77 M(-20.7%) |
| Mar 2002 | - | $501.00 K(-76.8%) | $4.75 M(-2.7%) |
| Dec 2001 | $4.88 M(+42.3%) | $2.16 M(+192.8%) | $4.88 M(+29.3%) |
| Sept 2001 | - | $739.00 K(-45.2%) | $3.78 M(-2.2%) |
| June 2001 | - | $1.35 M(+112.6%) | $3.86 M(+18.4%) |
| Mar 2001 | - | $634.00 K(-40.0%) | $3.26 M(-5.0%) |
| Dec 2000 | $3.43 M(+56.0%) | $1.06 M(+28.3%) | $3.43 M(+44.4%) |
| Sept 2000 | - | $823.00 K(+10.2%) | $2.38 M(+53.0%) |
| June 2000 | - | $747.00 K(-7.4%) | $1.55 M(+92.6%) |
| Mar 2000 | - | $807.00 K | $807.00 K |
| Dec 1999 | $2.20 M(+7.9%) | - | - |
| Dec 1998 | $2.04 M(+76.9%) | - | - |
| Dec 1997 | $1.15 M(+82.3%) | - | - |
| Dec 1996 | $632.00 K | - | - |
FAQ
- What is Sangamo Therapeutics annual revenue?
- What is the all time high annual revenue for Sangamo Therapeutics?
- What is Sangamo Therapeutics annual revenue year-on-year change?
- What is Sangamo Therapeutics quarterly revenue?
- What is the all time high quarterly revenue for Sangamo Therapeutics?
- What is Sangamo Therapeutics quarterly revenue year-on-year change?
- What is Sangamo Therapeutics TTM revenue?
- What is the all time high TTM revenue for Sangamo Therapeutics?
- What is Sangamo Therapeutics TTM revenue year-on-year change?
What is Sangamo Therapeutics annual revenue?
The current annual revenue of SGMO is $176.23 M
What is the all time high annual revenue for Sangamo Therapeutics?
Sangamo Therapeutics all-time high annual revenue is $176.23 M
What is Sangamo Therapeutics annual revenue year-on-year change?
Over the past year, SGMO annual revenue has changed by +$64.93 M (+58.34%)
What is Sangamo Therapeutics quarterly revenue?
The current quarterly revenue of SGMO is $49.41 M
What is the all time high quarterly revenue for Sangamo Therapeutics?
Sangamo Therapeutics all-time high quarterly revenue is $157.96 M
What is Sangamo Therapeutics quarterly revenue year-on-year change?
Over the past year, SGMO quarterly revenue has changed by +$40.01 M (+425.77%)
What is Sangamo Therapeutics TTM revenue?
The current TTM revenue of SGMO is $52.29 M
What is the all time high TTM revenue for Sangamo Therapeutics?
Sangamo Therapeutics all-time high TTM revenue is $241.03 M
What is Sangamo Therapeutics TTM revenue year-on-year change?
Over the past year, SGMO TTM revenue has changed by -$149.13 M (-74.04%)